• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·France·Healthcare·GDS.PA
Share

Ramsay Generale de Sante SA Stocks

€ 10.95Last Updated 17.07.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

€ 1.41B

€ 10.95
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Ramsay Générale de Santé S.A., headquartered in Paris, France, manages a network of hospitals across the nation. These facilities provide a wide spectrum of healthcare services, including specialized care in anesthesia, oncology, cardiology, dermatology, gastroenterology, gynecology, maternity, nephrology, neurosurgery, obesity management, ophthalmology, orthopedics, stomatology, pneumonology, psychiatry, radiology, and urology. Furthermore, they conduct various surgical procedures such as thoracic, vascular, and endovascular interventions. Founded in 1987, the company adopted its current name in December 2015, having previously been known as Générale de Santé SA. Ramsay Générale de Santé S.A. functions as a subsidiary of Ramsay Health Care Limited.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. In particular, the stock is of fair value on EV/EBITDA, undervalued on P/FC.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

18.07.2026 16:01

Small caps last week: Papa John's doubts, Perfect goes private, LLY-AtaiBeckley deal

18.07.2026 13:01

IBM's Worst Day, SK Hynix's Record Plunge, and the "Earnings Bubble" in AI

18.07.2026 03:31

Meta Is in Talks with Anthropic to Lease Data Centers for $10 Billion — The New York Times

18.07.2026 01:33

U.S. stocks closed lower. Chipmakers had their worst week in more than a year.

18.07.2026 00:58

Adidas won the marketing battle against Nike at the World Cup. Investors took note.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026